0000000000242893

AUTHOR

Maria Teresa Costantino

showing 8 related works from this author

SIRM-SIAAIC consensus, an Italian document on management of patients at risk of hypersensitivity reactions to contrast media

2020

Abstract Hypersensitivity reactions (HRs) to contrast media (CM) can be distinguished in immune-mediated (including allergic reactions) and non-immune-mediated reactions, even if clinical manifestations could be similar. Such manifestations range from mild skin eruptions to severe anaphylaxis, making it important for radiologists to know how to identify and manage them. A panel of experts from the Società Italiana di Radiologia Medica e Interventistica (SIRM) and the Società Italiana di Allergologia, Asma e Immunologia Clinica (SIAAIC) provided a consensus document on the management of patients who must undergo radiological investigations with CM. Consensus topics included: the risk stratif…

lcsh:Immunologic diseases. Allergyradiologic contrast media; hypersensitivity reactions; low-osmolar contrast agents; diagnosis; managementmedicine.medical_specialtyAllergyHypersensitivity reactionsReferralImmunologyReviewCulpritRadiologic contrast media03 medical and health sciences0302 clinical medicineDiagnosisHypersensitivity reactionmedicineImmunology and AllergyMedical historyIn patientLow-osmolar contrast agentsIntensive care medicineMolecular Biologybusiness.industryLow-osmolar contrast agentmedicine.diseaseManagement030228 respiratory systemRadiological weaponPremedicationbusinesslcsh:RC581-607AnaphylaxisDiagnosi030215 immunologyClinical and Molecular Allergy
researchProduct

Catching allergy by a simple questionnaire

2014

Background Identifying allergic rhinitis requires allergy testing, but the first-line referral for rhinitis are usually primary care physicians (PCP), who are not familiar with such tests. The availability of easy and simple tests to be used by PCP to suggest allergy should be very useful. Methods The Respiratory Allergy Prediction (RAP) test, based on 9 questions and previously validated by a panel of experts, was evaluated in this study. Results An overall number of 401 patients (48.6% males, age range 14–62 years) with respiratory symptoms was included. Of them, 89 (22.2%) showed negative results to SPT, while 312 (77.8%) had at least one positive result to SPT. Cohen’s kappa coefficient…

lcsh:Immunologic diseases. AllergyPulmonary and Respiratory MedicinePediatricsmedicine.medical_specialtyAllergyReferralAllergymedicine.medical_treatmentImmunologyAllergy testingPrimary careAllergy testingSettore MED/10 - Malattie Dell'Apparato RespiratorioPharmacistsAllergic rhinitisCohen's kappaAllergic rhinitimedicineImmunology and AllergyOriginal Researchbusiness.industrymedicine.diseaseAllergic rhinitis; Allergy; Allergy testing; Pharmacists; Primary care physicians; Immunology and AllergyTest (assessment)Primary care physicianNasal sprayPharmacistPrimary care physiciansAllergistslcsh:RC581-607business
researchProduct

Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI)

2020

According to the data derived from several national and international registries, including SANI (Severe Asthma Network Italy), and considering the strong impact that frequent or regular use of oral corticosteroid has on quality of life (QoL) of severe asthmatics, as well as on the costs for managing corticosteroid-related diseases, oral corticosteroid sparing up to withdrawal should be considered a primary outcome in the management of severe asthma. New biologics have clearly demonstrated that this effect is possible, with concomitant reduction in the rate of exacerbations and in symptom control. Then, there is no reason for using so frequently oral corticosteroid before having explored al…

ISAR International Severe Asthma RegistrySHARPPediatricsSevere asthmaSA severe asthmaBiologics Oral corticosteroids Real-life Registr Severe asthmaOmalizumabforced expiratory volume in the 1st secondFood &ampGrading of Recommendations Assessmentchronic rhinosinusitis with nasal polyposisFEV1chemistry.chemical_compound0302 clinical medicineQuality of lifeEMAReal WorldEuropean Medicines AgencyBiologics; Oral corticosteroids; Real-life; Registr; Severe asthmaOral corticosteroidsFDA Food & Drug AdministrationImmunology and Allergy030223 otorhinolaryngologySevere Heterogeneous Asthma Research collaborationmusculoskeletal neural and ocular physiologyReal-lifeCRSwNPOCSsBenralizumabDupilumabCRSwNP chronic rhinosinusitis with nasal polyposisGRADESHARP Severe Heterogeneous Asthma Research collaboration Patient-centredSevere Asthma Network in ItalyFDAmedicine.drugPulmonary and Respiratory Medicinelcsh:Immunologic diseases. Allergymedicine.medical_specialtyDrug AdministrationGINA Global Initiative for AsthmaRW Real WorldImmunologymacromolecular substancesRWSettore MED/10 - Malattie Dell'Apparato RespiratorioBiologicsInternational Severe Asthma RegistryISAR03 medical and health sciencesSADisease registrySARP Severe Asthma Research ProgramPatient-centredmedicineAsthmabusiness.industrySettore MED/09 - MEDICINA INTERNASANI Severe Asthma Network in ItalySANIBiological productmedicine.diseaseOCSs Oral CorticoSteroidsGINASARPSevere Asthma Research ProgramFEV1 forced expiratory volume in the 1st second030228 respiratory systemchemistrynervous systemRegistrEMA European Medicines AgencyDevelopment and EvaluationSevere asthma Biologics Oral corticosteroids Real-life Registrbusinesslcsh:RC581-607Global Initiative for AsthmaMepolizumabGRADE Grading of Recommendations Assessment Development and Evaluation
researchProduct

The Severe Asthma Network in Italy: Findings and Perspectives

2019

Background Severe Asthma Network in Italy (SANI) is a registry of patients recruited by accredited centers on severe asthma. Objective To analyze epidemiological, clinical, inflammatory, functional, and treatment characteristics of severe asthmatics from the SANI registry. Methods All consecutive patients with severe asthma were included into the registry, without exclusion criteria to have real-life data on demographics, asthma control, treatments (including biologics), inflammatory biomarkers, and comorbidities. Results A total of 437 patients (mean age: 54.1 years, 57.2% females, 70.7% atopics, 94.5% in Global Initiative for Asthma severity step V) were enrolled into the study. The mean …

AdultMalemedicine.medical_specialtyRegistrySevere asthmaExacerbationBronchiectasis; Comorbidities; Late-onset asthma; Nasal polyps; Registry; SANI; Severe asthma; Immunology and AllergyOmalizumabComorbiditySettore MED/10 - Malattie Dell'Apparato RespiratorioComorbiditiesAtopy03 medical and health sciencesBronchiectasi0302 clinical medicineFood allergyInternal medicineLate-onset asthmaNasal polypsBronchiectasis; Comorbidities; Late-onset asthma; Nasal polyps; Registry; SANI; Severe asthma; Adult; Aged; Asthma; Bronchiectasis; Comorbidity; Eosinophils; Female; Humans; Immunoglobulin E; Italy; Male; Middle Aged; Nasal Polyps; Registries; RhinitisMedicineHumansBronchiectasis Comorbidities Late-onset asthma Nasal polyps Registry SANI Severe asthma Immunology and AllergyImmunology and Allergy030212 general & internal medicineRegistriesAsthmaAgedRhinitisBronchiectasisbusiness.industryNasal polypSANIImmunoglobulin EMiddle Agedmedicine.diseaseAsthmaBronchiectasisEosinophils030228 respiratory systemItalyAsthma Control QuestionnaireFemaleComorbiditiebusinessMepolizumabmedicine.drug
researchProduct

Effects of a structured educational intervention in moderate-to-severe elderly asthmatic subjects.

2019

Background: Adherence to inhaled drugs is linked to patients’ satisfaction with their device, and an incorrect use can negatively affect the outcomes of asthma treatment. We speculated that this is particularly true in elderly asthmatic subjects. Aim: We performed a national pre-post interventional multicentre study, enrolling moderate-to-severe asthmatic subjects aged ≥65 ​years treated with fixed inhaled combination drugs by dry powder inhaler (DPI) or pressurized metered dose inhaler (pMDI). Adherence and critical errors were evaluated by means of validated questionnaires at first visit (V1) and after 3–6 months (V2). At V1, subjects underwent intensive training on the correct use of the…

Vital capacityACT asthma control testExacerbationSAE severe asthma exacerbationSF12chlorofluorocarbonsmental health composite scoreEDUCA elderly and device use in chronic asthmaPCS physical health composite scoreACT asthma control test; AHDS hospital anxiety depression scale; Asthma; CFC chlorofluorocarbons; Device misuse; EDUCA elderly and device use in chronic asthma; Education; Elderly; FEV1 forced expiratory volume 1s second; FVC forced vital capacity; ICS inhaled corticosteroids; LABA long-acting β2 agonist; LAMA long-acting muscarinic antagonists; MCS mental health composite score; PCS physical health composite score; PROs patient-reported outcomes; SAE severe asthma exacerbation; SF12 short form health survey; mMRC modified medical research councilEDUCAFEV10302 clinical medicineElderlyImmunology and AllergyMedicine030223 otorhinolaryngologybiologymMRC modified medical research councilsevere asthma exacerbationmodified medical research councilLAMASAELamaelderly and device use in chronic asthmaMetered-dose inhalerDry-powder inhalerDevice misusePROs patient-reported outcomesCFCPCSpatient-reported outcomesmMRClcsh:Immunologic diseases. AllergyPulmonary and Respiratory Medicinelong-acting β2 agonistmedicine.medical_specialtyImmunologyLABAphysical health composite scoreArticleLAMA long-acting muscarinic antagonistsAHDSEducation03 medical and health sciencesFEV1/FVC ratiolong-acting muscarinic antagonistsforced vital capacitySF12 short form health surveyAsthma; Device misuse; Education; ElderlyInternal medicineMCS mental health composite scoreforced expiratory volume 1s secondAsthmabusiness.industryFEV1 forced expiratory volume 1s secondInhalerasthma control testbiology.organism_classificationmedicine.diseaseCFC chlorofluorocarbonsACTICS inhaled corticosteroidsFVCAsthmaMCShospital anxiety depression scale030228 respiratory systemICSAHDS hospital anxiety depression scaleFVC forced vital capacityPROsshort form health surveyinhaled corticosteroidslcsh:RC581-607businessLABA long-acting β2 agonistThe World Allergy Organization journal
researchProduct

Severe asthma: One disease and multiple definitions

2021

Abstract Introduction There is, so far, no universal definition of severe asthma. This definition usually relies on: number of exacerbations, inhaled therapy, need for oral corticosteroids, and respiratory function. The use of such parameters varies in the different definitions used. Thus, according to the parameters chosen, each patient may result in having severe asthma or not. The aim of this study was to evaluate how the choice of a specific definition of severe asthma can change the allocation of patients. Methods Data collected from the Severe Asthma Network Italy (SANI) registry were analyzed. All the patients included were then reclassified according to the definitions of U-BIOPRED,…

Pulmonary and Respiratory Medicinemedicine.medical_specialtySevere asthmaSevere asthmaImmunologyNiceDiseaseSettore MED/10 - Malattie Dell'Apparato RespiratorioArticlePulmonary function testingInternal medicineBiological treatment; Classification; Definition; Severe asthmamedicineImmunology and AllergyRespiratory functioncomputer.programming_languageSevere asthma; Classification; Definition; Biological treatmentBiological therapiesbusiness.industrySettore MED/09 - MEDICINA INTERNADefinitionRC581-607ClassificationSevere asthma Classification Definition Biological treatmentBiological treatment Classification Definition Severe asthmaImmunologic diseases. AllergybusinessBiological treatmentcomputer
researchProduct

Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life

2021

Abstract Background and aims Severe asthma is burdened by frequent exacerbations and use of oral corticosteroids (OCS) which worsen patients’ health and increase healthcare spending. Aim of this study was to assess the clinical and economic effect of adding mepolizumab (MEP) for the treatment of these patients. Methods Patients >18 years old, referred to 8 asthma clinics, starting MEP between May 2017 and December 2018, were enrolled and followed-up for 12 months. Information in the 12 months before mepolizumab were collected retrospectively. The evaluation parameters included: OCS use, number of exacerbations/hospitalizations, concomitant therapies, comorbidity, and annual number of workin…

OR Odds RatioPediatricsSevere asthmaExacerbationAnti IL-5; Comorbidities; Mepolizumab; OCS; Pharmacoeconomics; Severe asthmagastroesophageal reflux diseaseSettore MED/10 - MALATTIE DELL'APPARATO RESPIRATORIOICS inhaled corticosteroidRate ratioOCS Oral Corticosteroidslaw.inventionComorbiditiesLAMA long acting muscarinic antagonist0302 clinical medicineRandomized controlled trialfractional nitric oxideInterquartile rangelawlong acting beta 2 agonistOdds RatioImmunology and AllergyRR Rate Ratio030223 otorhinolaryngologyPharmacoeconomicLOS Length of stayLOSIQRLAMAMEP MepolizumabORCISD Standard DeviationMEPPharmacoeconomicsACT Asthma Control TestComorbiditieCI Confidence Intervalsmedicine.druglcsh:Immunologic diseases. AllergyPulmonary and Respiratory Medicinemedicine.medical_specialtyinterquartile rangelong acting muscarinic antagonistImmunologyLABALABA long acting beta 2 agonistComorbidities Mepolizumab OCS Pharmacoeconomics Severe asthma Anti IL-5RRArticleRate Ratiochronic obstructive pulmonary disease03 medical and health sciencesPharmacoeconomicsOCS Oral CorticosteroidAsthma Control TestConfidence IntervalsFeNO fractional nitric oxideRCTs Randomized Controlled TrialmedicineCOPDGERD gastroesophageal reflux diseaseFeNOIQR interquartile rangeMepolizumabSDAsthmaRCTsOral Corticosteroidsbusiness.industryGERDmedicine.diseaseICS inhaled corticosteroidsACTComorbidityRandomized Controlled TrialsCI Confidence IntervalRCTs Randomized Controlled TrialsOCSCOPD chronic obstructive pulmonary disease030228 respiratory systemICSStandard DeviationLength of stayAnti IL-5inhaled corticosteroidslcsh:RC581-607businessMepolizumab
researchProduct

Allergic sensitization to common pets (cats/dogs) according to different possible modalities of exposure: an Italian Multicenter Study

2018

Abstract Background The query “are there animals at home?” is usually administered for collecting information on anamnesis. This modality to consider exposure to pet allergens constitutes a potential bias in epidemiological studies and in clinical practice. The aim of our study was to evaluate/quantify different modalities of exposure to cat/dog in inducing allergic sensitization. Methods Thirty Italian Allergy units participated in this study. Each centre was required to collect the data of at least 20 consecutive outpatients sensitized to cat/dog allergens. A standardized form reported all demographic data and a particular attention was paid in relieving possible modalities of exposure to…

lcsh:Immunologic diseases. AllergyAllergymedicine.medical_specialtyImmunologySettore MED/10 - Malattie Dell'Apparato RespiratorioPets exposureAllergic rhinitisAllergic sensitization03 medical and health sciences0302 clinical medicineInternal medicineEpidemiologyAllergic rhinitiDogHypersensitivitymedicineImmunology and Allergy030212 general & internal medicineAllergic rhinitis Allergic sensitization Bronchial asthma Cat; Dog Hypersensitivity Pets Pets exposure Immunology and Allergy Immunology Molecular BiologyBronchial asthmaMolecular BiologyAllergic rhinitis; Allergic sensitization; Bronchial asthma; Cat; Dog; Hypersensitivity; Pets; Pets exposureAllergic sensitizationAnamnesisCATSModalitiesbusiness.industryResearchCatPetsmedicine.diseasePet ownershipPet030228 respiratory systemMulticenter studyAllergic rhinitis; Allergic sensitization; Bronchial asthma; Cat; Dog; Hypersensitivity; Pets; Pets exposure; Immunology and Allergy; Immunology; Molecular Biologylcsh:RC581-607businessClinical and Molecular Allergy
researchProduct